Suppr超能文献

革兰氏阳性感染治疗的新进展。

Newer developments in the treatment of Gram-positive infections.

机构信息

Hartford Hospital, Center for Anti-Infective Research and Development, 80 Seymour Street, Hartford, CT 06102, USA.

出版信息

Expert Opin Pharmacother. 2009 Dec;10(17):2829-43. doi: 10.1517/14656560903357491.

Abstract

Gram-positive organisms are continually a major cause of infection. These organisms are ever-evolving and exhibit resistance to nearly all available agents. Historically, vancomycin was crowned the drug of choice for many of these organisms including methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, and penicillin-resistant Enterococcus spp. Many of these organisms have exhibited reduced susceptibility or frank resistance to vancomycin which has resulted in treatment failure. For this reason, new strategies in treating Gram-positive infections are a hot topic. There are two general approaches to waging this war: i) development of new antimicrobial agents; and ii) reinvigorating old antibiotics that still retain appreciable activity against Gram-positives. We review both antibiotic groupings with a focus on S. aureus, S. pneumoniae and Enterococcus spp.

摘要

革兰氏阳性菌一直是感染的主要原因。这些生物体在不断进化,并对几乎所有现有药物表现出耐药性。历史上,万古霉素被选为许多此类生物体的首选药物,包括耐甲氧西林金黄色葡萄球菌、耐青霉素肺炎链球菌和耐青霉素肠球菌。许多这些生物体对万古霉素表现出降低的敏感性或明显的耐药性,导致治疗失败。因此,治疗革兰氏阳性感染的新策略是一个热门话题。有两种一般的方法来进行这场战争:i)开发新的抗菌剂;ii)振兴仍然对革兰氏阳性菌具有相当活性的旧抗生素。我们回顾了这两种抗生素类别,重点是金黄色葡萄球菌、肺炎链球菌和肠球菌。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验